Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, has announced new employee inducement equity awards. The company granted stock options for 30,000 shares at $1.12 per share to one new non-executive employee and restricted stock units (RSUs) for 37,900 shares to two new non-executive employees.
The awards, approved by the Compensation Committee and granted under the company's Amended and Restated Inducement Equity Plan, include a 4-year vesting schedule. Stock options vest 25% after one year with remaining monthly installments over 36 months, while RSUs vest 25% annually over four years.
Fate Therapeutics (NASDAQ: FATE), un'azienda biofarmaceutica in fase clinica specializzata in immunoterapie cellulari derivate da iPSC, ha annunciato nuovi premi azionari per l'assunzione di dipendenti. La società ha concesso opzioni su azioni per 30.000 azioni a 1,12 $ per azione a un nuovo dipendente non esecutivo e unità azionarie vincolate (RSU) per 37.900 azioni a due nuovi dipendenti non esecutivi.
I premi, approvati dal Comitato per la Retribuzione e concessi nell'ambito del Piano Azionario di Induzione Emendato e Ristabilito dell'azienda, prevedono un programma di maturazione di 4 anni. Le opzioni su azioni maturano il 25% dopo un anno, con rate mensili per i restanti 36 mesi, mentre le RSU maturano il 25% ogni anno per quattro anni.
Fate Therapeutics (NASDAQ: FATE), una compañía biofarmacéutica en etapa clínica centrada en inmunoterapias celulares derivadas de iPSC, ha anunciado nuevas concesiones de acciones para empleados. La empresa otorgó opciones sobre 30,000 acciones a $1.12 por acción a un nuevo empleado no ejecutivo y unidades de acciones restringidas (RSU) por 37,900 acciones a dos nuevos empleados no ejecutivos.
Las concesiones, aprobadas por el Comité de Compensación y otorgadas bajo el Plan de Acciones de Inducción Enmendado y Reestablecido de la compañía, incluyen un programa de adquisición de derechos de 4 años. Las opciones sobre acciones se adquieren en un 25% después de un año, con cuotas mensuales durante los siguientes 36 meses, mientras que las RSU se adquieren en un 25% anual durante cuatro años.
Fate Therapeutics (NASDAQ: FATE)는 iPSC 유래 세포 면역치료제에 중점을 둔 임상 단계의 바이오제약 회사로, 신규 직원 유인 주식 보상을 발표했습니다. 회사는 한 명의 비임원 신입 직원에게 주당 1.12달러에 30,000주에 대한 스톡 옵션을, 두 명의 비임원 신입 직원에게 37,900주에 대한 제한 주식 단위(RSU)를 부여했습니다.
이 보상은 보상위원회의 승인을 받아 회사의 수정 및 재정비된 유인 주식 계획에 따라 부여되었으며, 4년 베스팅 일정이 포함되어 있습니다. 스톡 옵션은 1년 후 25%가 베스팅되며, 나머지는 36개월 동안 매월 분할 베스팅되고, RSU는 4년에 걸쳐 매년 25%씩 베스팅됩니다.
Fate Therapeutics (NASDAQ : FATE), une société biopharmaceutique en phase clinique spécialisée dans les immunothérapies cellulaires dérivées de iPSC, a annoncé de nouvelles attributions d'actions incitatives pour les employés. La société a accordé des options d'achat d'actions pour 30 000 actions à 1,12 $ par action à un nouvel employé non cadre et des unités d'actions restreintes (RSU) pour 37 900 actions à deux nouveaux employés non cadres.
Ces attributions, approuvées par le Comité de rémunération et accordées dans le cadre du Plan d'attribution d'actions incitatives modifié et révisé de la société, comprennent un calendrier d'acquisition de droits de 4 ans. Les options d'achat d'actions acquièrent 25 % des droits après un an, avec des versements mensuels sur les 36 mois suivants, tandis que les RSU acquièrent 25 % des droits chaque année pendant quatre ans.
Fate Therapeutics (NASDAQ: FATE), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Fokus auf iPSC-abgeleitete zelluläre Immuntherapien, hat neue Aktienanreizprämien für Mitarbeiter angekündigt. Das Unternehmen gewährte Aktienoptionen für 30.000 Aktien zu 1,12 $ pro Aktie an einen neuen nicht geschäftsführenden Mitarbeiter und Restricted Stock Units (RSUs) für 37.900 Aktien an zwei neue nicht geschäftsführende Mitarbeiter.
Die Prämien, genehmigt vom Vergütungsausschuss und gewährt im Rahmen des geänderten und neu gefassten Inducement Equity Plans des Unternehmens, beinhalten einen 4-jährigen Vesting-Zeitplan. Aktienoptionen werden zu 25 % nach einem Jahr fällig, mit monatlichen Raten über die verbleibenden 36 Monate, während RSUs jährlich zu 25 % über vier Jahre vesten.
- None.
- None.
SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on July 2, 2025 the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 30,000 shares of the Company’s common stock at an exercise price per share of
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
FAQ
What equity awards did Fate Therapeutics (FATE) grant to new employees in July 2025?
What is the vesting schedule for Fate Therapeutics' July 2025 employee stock options?
How do the RSUs vest in Fate Therapeutics' July 2025 employee inducement awards?
What was the exercise price for Fate Therapeutics' July 2025 employee stock options?
